The development of drugs that inhibit SOCS3 activity or expression may, therefore, represent a potential strategy for treating type 2 diabetes, obesity, and other metabolic disorders [37]. Here, SOCS3 is linked to obesity due to melanocortin 4 receptor deficiency.